FATE FY2025 EPS Forecast Increased by Cantor Fitzgerald
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Investment analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for Fate Therapeutics in a research note issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now forecasts that the biopharmaceutical company will earn ($1.20) per share for the year, up from their previous forecast of […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Investment analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for Fate Therapeutics in a research note issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now forecasts that the biopharmaceutical company will earn ($1.20) per share for the year, up from their previous forecast of […]
